REMSEQ
LIVE

Serial Number

98195945

Owner

Remix Therapeutics Inc.

Attorney

Christina Licursi

Filing Date

Sep 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

REMSEQ Trademark

Serial Number: 98195945

REMSEQ is a trademark filed by Remix Therapeutics Inc. on September 25, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Remix Therapeutics Inc. (8 trademarks)

400 Technology Square
Cambridge, MA 02139

Entity Type: 03

Trademark Details

Filing Date

September 25, 2023

Registration Date

Not Registered

Published for Opposition

December 24, 2024

Goods & Services

development of gene-based medicines; gene therapy and modulation research; laboratory research in the fields of degrading and enhancing RNA including exon skipping and rescue genetic lesions; Medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation

Pharmaceutical preparations for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; pharmaceutical preparations for the use in gene therapy for the treatment of genetic disorders, immune system related diseases and disorders, metabolic diseases and disorders, hematological diseases and disorders, cancer, neurological diseases and disorders, reproductive diseases and disorders, gynecological diseases and disorders, inflammatory diseases and disorders, cardiological diseases and disorders, respiratory diseases and disorders, gastroenterological diseases and disorders, musculoskeletal diseases and disorders, ophthalmological diseases and disorders, and dermatological diseases and disorders; preparations for detecting mutation in RNA genes for medical purposes

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 19, 2026 EXRA
SOU EXTENSION 2 GRANTED
Feb 18, 2026 EX2G
SOU EXTENSION 2 FILED
Feb 18, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 18, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 18, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 18, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 18, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 23, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 23, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 23, 2025 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 18, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 24, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 24, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 18, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 21, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 21, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 21, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 21, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 21, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 3, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 3, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 3, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 26, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 17, 2024 CNRT
ASSIGNED TO EXAMINER
May 16, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2023 NWOS